<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32776498</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-1707</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Pharmacology research &amp; perspectives</Title><ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation></Journal><ArticleTitle>Effects of RAGE inhibition on the progression of the disease in hSOD1<sup>G93A</sup> ALS mice.</ArticleTitle><Pagination><StartPage>e00636</StartPage><MedlinePgn>e00636</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00636</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.636</ELocationID><Abstract><AbstractText>Astrocytes play a key role in the progression of amyotrophic lateral sclerosis (ALS) by actively inducing the degeneration of motor neurons. Motor neurons isolated from receptor for advanced glycation end products (RAGE)-knockout mice are resistant to the neurotoxic signal derived from ALS-astrocytes. Here, we confirmed that in a co-culture model, the neuronal death induced by astrocytes over-expressing the ALS-linked mutant hSOD1<sup>G93A</sup> is prevented by the addition of the RAGE inhibitors FPS-ZM1 or RAP. These inhibitors also prevented the motor neuron death induced by spinal cord extracts from symptomatic hSOD1<sup>G93A</sup> mice. To evaluate the relevance of this neurotoxic mechanism in ALS pathology, we assessed the therapeutic potential of FPS-ZM1 in hSOD1<sup>G93A</sup> mice. FPS-ZM1 treatment significantly improved hind-limb grip strength in hSOD1<sup>G93A</sup> mice during the progression of the disease, reduced the expression of atrophy markers in the gastrocnemius muscle, improved the survival of large motor neurons, and reduced gliosis in the ventral horn of the spinal cord. However, we did not observe a statistically significant effect of the drug in symptoms onset nor in the survival of hSOD1<sup>G93A</sup> mice. Maintenance of hind-limb grip strength was also observed in hSOD1<sup>G93A</sup> mice with RAGE haploinsufficiency [hSOD1<sup>G93A</sup> ;RAGE(+/-)], further supporting the beneficial effect of RAGE inhibition on muscle function. However, no benefits were observed after complete RAGE ablation. Moreover, genetic RAGE ablation significantly shortened the median survival of hSOD1<sup>G93A</sup> mice. These results indicate that the advance of new therapies targeting RAGE in ALS demands a better understanding of its physiological role in a cell type/tissue-specific context.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Pharmacology Research &amp; Perspectives published by John Wiley &amp; Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biomedical Sciences Training Program, Department of Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Killoy</LastName><ForeName>Kelby M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Biomedical Sciences Training Program, Department of Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Marcelo R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-1039-4210</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Wisconsin-Madison, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Yasuhiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pehar</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1231-4563</Identifier><AffiliationInfo><Affiliation>Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education Clinical Center, Veterans Affairs Medical Center, Madison, WI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01NS100835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018113</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA138313</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM103542</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Res Perspect</MedlineTA><NlmUniqueID>101626369</NlmUniqueID><ISSNLinking>2052-1707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593873">Ager protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067759">Receptor for Advanced Glycation End Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067759" MajorTopicYN="N">Receptor for Advanced Glycation End Products</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atrogin-1</Keyword><Keyword MajorTopicYN="N">MuRF1</Keyword><Keyword MajorTopicYN="N">advanced glycation end products receptor</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">motor neurons</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32776498</ArticleId><ArticleId IdType="pmc">PMC7415959</ArticleId><ArticleId IdType="doi">10.1002/prp2.636</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez&#x2010;Moreno R, et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part I, background and methods. Brain Behav. 2013;3(4):335&#x2010;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869677</ArticleId><ArticleId IdType="pubmed">24381807</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez&#x2010;Moreno R, et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav. 2013;3(4):431&#x2010;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869683</ArticleId><ArticleId IdType="pubmed">24381813</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, Kranz JE, Cole J, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9(1):4&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11(1&#x2013;2):38&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non&#x2010;cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761&#x2010;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3):251&#x2010;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Pehar M, Cassina P, Beckman JS, Barbeito L. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR&#x2010;dependent motor neuron apoptosis. J Neurochem. 2006;97(3):687&#x2010;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524372</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS&#x2010;linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615&#x2010;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K, Ferraiuolo L, Miranda CJ, et al. Direct conversion of patient fibroblasts demonstrates non&#x2010;cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci USA. 2014;111(2):829&#x2010;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet&#x2010;Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(9):824&#x2010;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Vargas MR, Harlan BA, et al. Nitration and glycation turn mature NGF into a toxic factor for motor neurons: a role for p75(NTR) and RAGE signaling in ALS. Antioxid Redox Signal. 2018;28(18):1587&#x2010;1602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962334</ArticleId><ArticleId IdType="pubmed">28537420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Hirano A, Hedley&#x2010;Whyte TE, et al. Selective formation of certain advanced glycation end products in spinal cord astrocytes of humans and mice with superoxide dismutase&#x2010;1 mutation. Acta Neuropathol. 2002;104(2):171&#x2010;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111360</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, Iyer AM, Spliet W, et al. Toll&#x2010;like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 2011;179:233&#x2010;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">21303685</ArticleId></ArticleIdList></Reference><Reference><Citation>Juranek JK, Daffu GK, Wojtkiewicz J, Lacomis D, Kofler J, Schmidt AM. Receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis. Front Cell Neurosci. 2015;9:485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4686801</ArticleId><ArticleId IdType="pubmed">26733811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi S, Shinpo K, Ogata A, et al. Detection of N epsilon&#x2010;(carboxymethyl)lysine (CML) and non&#x2010;CML advanced glycation end&#x2010;products in the anterior horn of amyotrophic lateral sclerosis spinal cord. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(2):63&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">12215227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM. Absence of toll&#x2010;like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2015;12:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431460</ArticleId><ArticleId IdType="pubmed">25962427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilzecka J. Serum&#x2010;soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009;120(2):119&#x2010;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">19053950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson BI, Carter AM, Harja E, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008;22(5):1572&#x2010;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">18089847</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Mendez JD, Mendez&#x2010;Valenzuela V, Aguilar&#x2010;Hernandez MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25(11):2185&#x2010;2197.</Citation><ArticleIdList><ArticleId IdType="pubmed">23838007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94(1):55&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">23543766</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S, Miranda CJ, Braun L, et al. Major histocompatibility complex class I molecules protect motor neurons from astrocyte&#x2010;induced toxicity in amyotrophic lateral sclerosis. Nat Med. 2016;22(4):397&#x2010;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823173</ArticleId><ArticleId IdType="pubmed">26928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E, Cassina A, Mart&#xed;nez&#x2010;Palma L, et al. Neuroprotective effects of the mitochondria&#x2010;targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med. 2014;70:204&#x2010;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">24582549</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci. 2008;28(50):13574&#x2010;13581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Killoy KM, Pehar M, Liu L, Auwerx J, Vargas MR. Evaluation of the NAD(+) biosynthetic pathway in ALS patients and effect of modulating NAD(+) levels in hSOD1&#x2010;linked ALS mouse models. Exp Neurol. 2020;327:113219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089832</ArticleId><ArticleId IdType="pubmed">32014438</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhtman A, Ramasamy R, Schmidt AM. Glycation &amp; the RAGE axis: targeting signal transduction through DIAPH1. Expert Rev Proteomics. 2017;14(2):147&#x2010;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5535775</ArticleId><ArticleId IdType="pubmed">27967251</ArticleId></ArticleIdList></Reference><Reference><Citation>Juranek JK, Daffu GK, Geddis MS, et al. Soluble RAGE treatment delays progression of amyotrophic lateral sclerosis in SOD1 mice. Front Cell Neurosci. 2016;10:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860390</ArticleId><ArticleId IdType="pubmed">27242430</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid&#x2010;beta peptide transport across the blood&#x2010;brain barrier and accumulation in brain. Nat Med. 2003;9(7):907&#x2010;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Singh I, Sagare AP, et al. A multimodal RAGE&#x2010;specific inhibitor reduces amyloid beta&#x2010;mediated brain disorder in a mouse model of Alzheimer disease. J Clin Investig. 2012;122(4):1377&#x2010;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314449</ArticleId><ArticleId IdType="pubmed">22406537</ArticleId></ArticleIdList></Reference><Reference><Citation>Myint K&#x2010;M, Yamamoto Y, Doi T, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low&#x2010;molecular weight heparin. Diabetes. 2006;55(9):2510&#x2010;2522.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, O'Riordan KJ, Burns&#x2010;Cusato M, et al. Altered longevity&#x2010;assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell. 2010;9(2):174&#x2010;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848983</ArticleId><ArticleId IdType="pubmed">20409077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Cassina P, Vargas MR, et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem. 2004;89(2):464&#x2010;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056289</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Beeson G, Beeson CC, Johnson JA, Vargas MR. Mitochondria&#x2010;targeted catalase reverts the neurotoxicity of hSOD1G(9)(3)A astrocytes without extending the survival of ALS&#x2010;linked mutant hSOD1 mice. PLoS ONE. 2014;9(7):e103438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108402</ArticleId><ArticleId IdType="pubmed">25054289</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Vargas MR, Robinson KM, et al. Peroxynitrite transforms nerve growth factor into an apoptotic factor for motor neurons. Free Radic Biol Med. 2006;41(11):1632&#x2010;1644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17145551</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P, Peluffo H, Pehar M, et al. Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J Neurosci Res. 2002;67(1):21&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">11754077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Ball LE, Sharma DR, et al. Changes in protein expression and lysine acetylation induced by decreased glutathione levels in astrocytes. Mol Cell Proteomics. 2016;15(2):493&#x2010;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739669</ArticleId><ArticleId IdType="pubmed">26486419</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam T, Ramachandran V, Gomez SB, Schmidt AM, Logsdon CD. S100P&#x2010;derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012;18(16):4356&#x2010;4364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845828</ArticleId><ArticleId IdType="pubmed">22718861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler. 2007;8(4):217&#x2010;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653919</ArticleId></ArticleIdList></Reference><Reference><Citation>Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abeta&#x2010;induced perturbation of neuronal function in transgenic mice. EMBO J. 2004;23(20):4096&#x2010;4105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524347</ArticleId><ArticleId IdType="pubmed">15457210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: a potential target for Abeta&#x2010;mediated cellular perturbation in Alzheimer's disease. Curr Mol Med. 2007;7(8):735&#x2010;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">18331231</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Lue LF, Yan S, et al. RAGE&#x2010;dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 2010;24(4):1043&#x2010;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3231946</ArticleId><ArticleId IdType="pubmed">19906677</ArticleId></ArticleIdList></Reference><Reference><Citation>Teismann P, Sathe K, Bierhaus A, et al. Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging. 2012;33(10):2478&#x2010;2490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712169</ArticleId><ArticleId IdType="pubmed">22227007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF&#x2010;04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE). Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25(3):206&#x2010;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346183</ArticleId><ArticleId IdType="pubmed">21192237</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE&#x2010;Abeta interactions in Alzheimer disease. Neurology. 2014;82(17):1536&#x2010;1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011464</ArticleId><ArticleId IdType="pubmed">24696507</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker D, Lue LF, Paul G, Patel A, Sabbagh MN. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(3):393&#x2010;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502774</ArticleId><ArticleId IdType="pubmed">25586103</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L. Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer's disease. J Prev Alzheimers Dis. 2018;5(2):149&#x2010;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">29616709</ArticleId></ArticleIdList></Reference><Reference><Citation>Valcarce C, Dunn I, Burstein AH. Linking diabetes and Alzheimer's disease through rage: a retrospective analysis of Azeliragon Phase 2 and Phase 3 studies Alzheimer's Association International Conference 2019. 2019;15(Issue 7S_Part_24):P1263. Abstract O1264&#x2013;1211&#x2010;1204.</Citation></Reference><Reference><Citation>Chiu C&#x2010;Y, Yang R&#x2010;S, Sheu M&#x2010;L, et al. Advanced glycation end&#x2010;products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE&#x2010;mediated, AMPK&#x2010;down&#x2010;regulated, Akt pathway. J Pathol. 2016;238(3):470&#x2010;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">26586640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagheddu R, Chiappalupi S, Salvadori L, Riuzzi F, Donato R, Sorci G. Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy. Hum Mol Genet. 2018;27(21):3734&#x2010;3746.</Citation><ArticleIdList><ArticleId IdType="pubmed">30085099</ArticleId></ArticleIdList></Reference><Reference><Citation>Riuzzi F, Sorci G, Sagheddu R, Chiappalupi S, Salvadori L, Donato R. RAGE in the pathophysiology of skeletal muscle. J Cachexia Sarcopenia Muscle. 2018;9(7):1213&#x2010;1234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351676</ArticleId><ArticleId IdType="pubmed">30334619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappalupi S, Sorci G, Vukasinovic A, et al. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia. J Cachexia Sarcopenia Muscle. 2020. 10.1002/jcsm.12561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12561</ArticleId><ArticleId IdType="pmc">PMC7432590</ArticleId><ArticleId IdType="pubmed">32159297</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;ger B, Vergani L, Sorar&#xf9; G, et al. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin&#x2010;1. FASEB J. 2006;20(3):583&#x2010;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507768</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong LL, Gooch C, Szabolcs M, et al. RAGE: a journey from the complications of diabetes to disorders of the nervous system &#x2010; striking a fine balance between injury and repair. Restor Neurol Neurosci. 2005;23(5&#x2013;6):355&#x2010;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">16477098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorci G, Riuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta. 2013;1833(1):101&#x2010;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">23103427</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla L, Martorana F, Guidotti G, Rossi D. Dysregulation of astrocytic HMGB1 signaling in amyotrophic lateral sclerosis. Front Neurosci. 2018;12:622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123379</ArticleId><ArticleId IdType="pubmed">30210286</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Harlan BA, Killoy KM, Vargas MR. Role and therapeutic potential of astrocytes in amyotrophic lateral sclerosis. Curr Pharm Des. 2017;23(33):5010&#x2010;5021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740017</ArticleId><ArticleId IdType="pubmed">28641533</ArticleId></ArticleIdList></Reference><Reference><Citation>Valori CF, Guidotti G, Brambilla L, Rossi D. Astrocytes in motor neuron diseases. Adv Exp Med Biol. 2019;1175:227&#x2010;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">31583591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekestern E. Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener Dis. 2004;1(2&#x2013;3):88&#x2010;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908980</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Bogaert E, Dewil M, et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci USA. 2007;104(37):14825&#x2010;14830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1976195</ArticleId><ArticleId IdType="pubmed">17804792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci. 1995;3(6):348&#x2010;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">9021256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Higginbottom A, Heath PR, et al. Dysregulation of astrocyte&#x2010;motoneuron cross&#x2010;talk in mutant superoxide dismutase 1&#x2010;related amyotrophic lateral sclerosis. Brain. 2011;134(Pt 9):2627&#x2010;2641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170534</ArticleId><ArticleId IdType="pubmed">21908873</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci. 2011;36(12):625&#x2010;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">22019011</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem. 2008;283(40):27255&#x2010;27269.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667420</ArticleId></ArticleIdList></Reference><Reference><Citation>Song JS, Kang CM, Park CK, et al. Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF&#x2010;beta&#x2010;induced alveolar epithelial to mesenchymal transition. Exp Mol Med. 2011;43(9):517&#x2010;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203242</ArticleId><ArticleId IdType="pubmed">21743278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V, Fleming T, Terjung S, et al. Homeostatic nuclear RAGE&#x2010;ATM interaction is essential for efficient DNA repair. Nucleic Acids Res. 2017;45(18):10595&#x2010;10613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737477</ArticleId><ArticleId IdType="pubmed">28977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER. A gain&#x2010;of&#x2010;function of an amyotrophic lateral sclerosis&#x2010;associated Cu, Zn&#x2010;superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci USA. 1996;93(12):5709&#x2010;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39125</ArticleId><ArticleId IdType="pubmed">8650157</ArticleId></ArticleIdList></Reference><Reference><Citation>He C, Ryan AJ, Murthy S, Carter AB. Accelerated development of pulmonary fibrosis via Cu, Zn&#x2010;superoxide dismutase&#x2010;induced alternative activation of macrophages. J Biol Chem. 2013;288(28):20745&#x2010;20757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711337</ArticleId><ArticleId IdType="pubmed">23720777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>